West Pharmaceutical Services (WST) Capital Expenditures (2009 - 2026)

West Pharmaceutical Services has disclosed Capital Expenditures across 18 years of filings, most recently posting $43.2 million for Q2 2026.

• In Q2 2026, Capital Expenditures fell 42.55% year-over-year to $43.2 million; the TTM figure through Jun 2026 stood at $225.3 million (down 32.28% YoY), while the FY2025 annual figure was $285.9 million, down 24.16% from the prior year.
• Capital Expenditures came in at $43.2 million for Q2 2026 at West Pharmaceutical Services, up from $42.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $108.7 million in Q4 2023 to a low of $42.7 million in Q1 2026.
• Average Capital Expenditures over 5 years is $77.5 million, with a median of $75.8 million recorded in 2023.
• Year-over-year, Capital Expenditures soared 65.74% in 2023 and tumbled 42.55% in 2026.
• Over 5 years, Capital Expenditures stood at $94.9 million in 2022, then advanced by 14.54% to $108.7 million in 2023, then slipped by 3.5% to $104.9 million in 2024, then retreated by 27.45% to $76.1 million in 2025, then sank by 43.23% to $43.2 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $43.2 million in Q2 2026, $42.7 million in Q1 2026, and $76.1 million in Q4 2025.